GERN · Geron Corp · Webcasts, Transcripts & Audio
$1.21
-0.02 (-1.63%)
At close · Oct 1
Return incl. dividend (before tax)
Market Cap
$809.52M
Shares
642.47M
Volume · Oct 1
13.26M
Avg daily vol (3M)
10.33M
Geron Corp Webcasts
Earnings calls, investor updates, investor days and conferences for Geron Corp (GERN), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▲172.5%
$297,000
−$41.05M
'22 Q3
22-11-03
▼90.1%
$103,000
−$42.63M
'22 Q4
23-03-16
▼82.9%
$21,000
−$38.12M
'23 Q1
23-04-20
▼60.3%
$29,000
−$49.23M
'23 Q2
23-08-03
▼44.8%
$164,000
−$44.80M
'23 Q3
23-11-02
▼77.7%
$23,000
−$51.97M
'23 Q4
24-01-08
▲1347.6%
$304,000
−$55.39M
'24 Q1
24-05-02
▲2941.4%
$882,000
−$67.38M
'24 Q2
24-08-08
▲17138.4%
$28.27M
−$26.45M
'24 Q3
24-11-07
▲12927.3%
$39.60M
−$19.84M
'25 Q1
25-05-07
▲5459.6%
$49.04M
−$16.38M
'25 Q2
25-08-06
▲67.1%
$47.23M
−$18.43M
'25 Q3
25-11-05
▲30.9%
$51.84M
−$3.64M
'26 Q1
26-05-06
LATEST
▲17.2%
$57.48M
−$16.68M
'26 Q2
26-08-05
Conference
Investor event
2026-09-15
Geron Corp (GERN) September 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q2
2026-08-05
Geron Corp (GERN) Q2 2026 Earnings Call Transcript
Confident tone
Ritello commercial performance and demand growth
Real-world evidence and medical engagement
Phase 3 IMpactMS trial in myelofibrosis
Revenue
$57.48M
▲ 17.2% YoY Diluted EPS
$-0.02
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-06-08
Geron Corp (GERN) June 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-05-06
Geron Corp (GERN) Q1 2026 Earnings Call Transcript
Positive tone
RYTELO U.S. commercial growth
European commercial and pricing strategy
Medical affairs / hematology engagement
Revenue
$51.84M
▲ 30.9% YoY Diluted EPS
$-0.01
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-04-13
Geron Corp (GERN) April 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-03-10
Geron Corp (GERN) March 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY25 · Q4
2026-02-25
Geron Corp (GERN) Q4 2025 Earnings Call Transcript
Confident tone
Rytelo commercial growth and second-line MDS opportunity
3D surround sound and field force execution
2026 financial guidance and path to profitability
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-05
Geron Corp (GERN) Q3 2025 Earnings Call Transcript
Positive tone
RYTELO commercial performance and growth
Healthcare provider awareness and education
Commercial execution and strategy reset
Revenue
$47.23M
▲ 67.1% YoY Diluted EPS
$-0.03
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-06
Geron Corp (GERN) Q2 2025 Earnings Call Transcript
Positive tone
RYTELO U.S. commercial performance
HCP awareness and earlier-line adoption
EU launch and partnering strategy
Revenue
$49.04M
▲ 5459.6% YoY Diluted EPS
$-0.02
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-07
Geron Corp (GERN) Q1 2025 Earnings Call Transcript
Positive tone
RYTELO U.S. commercial launch
IMPACT MS Phase 3 in myelofibrosis
Commercial strategy enhancements
Revenue
$39.60M
▲ 12927.3% YoY Diluted EPS
$-0.03
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-01-13
Geron Corp (GERN) Q4 2024 Earnings Call Transcript
Positive tone
RYTELO commercial launch and revenue trends
Myelofibrosis IMpactMF Phase 3 trial
Duration of treatment
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-07
Geron Corp (GERN) Q3 2024 Earnings Call Transcript
Confident tone
RYTELO U.S. Commercial Launch Performance
Lower-Risk MDS Market Opportunity and Demand
Financing Transactions and Capital Position
Revenue
$28.27M
▲ 17138.4% YoY Diluted EPS
$-0.04
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-08
Geron Corp (GERN) Q2 2024 Earnings Call Transcript
Confident tone
RYTELO commercial launch
NCCN Guidelines inclusion
Lower-risk MDS market opportunity
Revenue
$882,000
▲ 2941.4% YoY Diluted EPS
$-0.10
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-02
Geron Corp (GERN) Q1 2024 Earnings Call Transcript
Confident tone
U.S. Launch of Imetelstat in Lower-Risk MDS
Market Differentiation and Unmet Need
FDA / Regulatory Progress
Revenue
$304,000
▲ 1347.6% YoY Diluted EPS
$-0.09
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-01-08
Geron Corp (GERN) Q4 2023 Earnings Call Transcript
Confident tone
FDA regulatory review and ODAC
IMerge Phase 3 clinical data in lower-risk MDS
IMpactMF Phase 3 in myelofibrosis
Revenue
$23,000*
▼ 77.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-02
Geron Corp (GERN) Q3 2023 Earnings Call Transcript
Revenue
$164,000
▼ 44.8% YoY Diluted EPS
$-0.08
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-03
Geron Corp (GERN) Q2 2023 Earnings Call Transcript
Revenue
$29,000
▼ 60.3% YoY Diluted EPS
$-0.09
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-04-20
Geron Corp (GERN) Q1 2023 Earnings Call Transcript
Revenue
$21,000
▼ 82.9% YoY Diluted EPS
$-0.07
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-03-16
Geron Corp (GERN) Q4 2022 Earnings Call Transcript
Revenue
$103,000*
▼ 90.1% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-03
Geron Corp (GERN) Q3 2022 Earnings Call Transcript
Revenue
$297,000
▲ 172.5% YoY Diluted EPS
$-0.10
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-11
Geron Corp (GERN) Q2 2022 Earnings Call Transcript
Revenue
$73,000
▼ 31.8% YoY Diluted EPS
$-0.07
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-04-13
Geron Corp (GERN) Q1 2022 Earnings Call Transcript
Revenue
$123,000
▼ 10.2% YoY Diluted EPS
$-0.09
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-01-10
Geron Corp (GERN) Q4 2021 Earnings Call Transcript
Revenue
$1.04M*
▲ 1980% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-10
Geron Corp (GERN) Q3 2021 Earnings Call
Revenue
$109,000
▲ 0.9% YoY Diluted EPS
$-0.08
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-16
Geron Corp (GERN) Q2 2021 Earnings Call Transcript
Revenue
$107,000
▲ 148.8% YoY Diluted EPS
$-0.09
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-10
Geron Corp (GERN) Q1 2021 Earnings Call Transcript
Revenue
$137,000
▲ 163.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-03-11
Geron Corp (GERN) Q4 2020 Earnings Call Transcript
Revenue
$50,000*
▼ 70.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-11-05
Geron Corp (GERN) Q3 2020 Earnings Call Transcript
Revenue
$108,000
▼ 17.6% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-08-06
Geron Corp (GERN) Q2 2020 Earnings Call Transcript
Revenue
$43,000
▼ 57.4% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-05-28
Geron Corp (GERN) Q1 2020 Earnings Call Transcript
Revenue
$52,000
▼ 8.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Showing 1–30 of 30 webcasts